The pharmaceutical industry is undergoing a period of significant change. Increased scrutiny of operational and research practices together with questions about the safety of marketed drugs have bred uncertainty in what has traditionally been considered a "blue-chip" business. Most analysts agree that the industry is entering a period of fundamental transformation – moving from the era of "blockbuster" drugs to a new model of drug development commonly referred to as "personalised medicine". Yet, the promise of this revolution is still in its infancy. Consequently, conventional industry approaches to research and development (R&D) will continue for the foreseeable future
PricewaterhouseCoopers is the professional services organisation of choice for the world's leading pharmaceutical and healthcare products companies. We serve all sectors of the industry: proprietary and generic drug manufacturers, wholesalers and distributors, specialty drug companies, medical device suppliers, pharmacy benefit managers, contract research and sales organisations, and industry associations.
PwC’s capabilities span the areas of audit, tax and business advisory, and include customised services related to regulatory compliance, risk management, and performance improvement. We are experienced in all aspects of company operations including those relating to R&D, manufacturing, and sales and marketing
